The Health Resources and Services Administration today delayed to July 1, 2018 the effective date of its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers. “We are delaying the effective date of the Jan. 5, 2017, final rule to July 1, 2018, because the delay will provide stakeholders with additional time to come into compliance and provide time to consider the substantial questions of fact, law and policy raised by the rule,” the agency said. AHA had opposed any further delay of the rule, which has been subject to multiple delays since January. “The agency’s rulemaking on these issues began seven years ago, shortly after the passage of the ACA,” AHA Executive Vice President Tom Nickels said in comments submitted last week. “This process included an advance notice of proposed rulemaking, a notice of proposed rulemaking, a final rule and now an interim final rule. Therefore, there have been extensive opportunities for stakeholders to provide feedback and ample time for HRSA to consider such feedback.”

Related News Articles

Headline
The Centers for Medicare…
Blog
AHA staff recently visited two rural hospitals to see and hear firsthand how leaders are engaging in innovative practices to increase accessibility and…
Headline
The Centers for Medicare…
Headline
Tax-exempt hospitals in the 340B drug savings program provided $56.1 billion in total benefits to their communities in 2016, the most recent year for which…
Headline
The Centers for Medicare…
Headline
The Fund for Access to Inpatient Rehabilitation late yesterday announced that the government will settle backlogged Medicare inpatient rehabilitation facility…